Methodological approach to determine minor, considerable, and major treatment effects in the early benefit assessment of new drugs
Open Access
- 2 July 2015
- journal article
- research article
- Published by Wiley in Biometrical Journal
- Vol. 58 (1) , 43-58
Abstract
At the beginning of 2011, the early benefit assessment of new drugs was introduced in Germany with the Act on the Reform of the Market for Medicinal Products (AMNOG). The Federal Joint Committee (G‐BA) generally commissions the Institute for Quality and Efficiency in Health Care (IQWiG) with this type of assessment, which examines whether a new drug shows an added benefit (a positive patient‐relevant treatment effect) over the current standard therapy. IQWiG is required to assess the extent of added benefit on the basis of a dossier submitted by the pharmaceutical company responsible. In this context, IQWiG was faced with the task of developing a transparent and plausible approach for operationalizing how to determine the extent of added benefit. In the case of an added benefit, the law specifies three main extent categories (minor, considerable, major). To restrict value judgements to a minimum in the first stage of the assessment process, an explicit and abstract operationalization was needed. The present paper is limited to the situation of binary data (analysis of 2 × 2 tables), using the relative risk as an effect measure. For the treatment effect to be classified as a minor, considerable, or major added benefit, the methodological approach stipulates that the (two‐sided) 95% confidence interval of the effect must exceed a specified distance to the zero effect. In summary, we assume that our approach provides a robust, transparent, and thus predictable foundation to determine minor, considerable, and major treatment effects on binary outcomes in the early benefit assessment of new drugs in Germany. After a decision on the added benefit of a new drug by G‐BA, the classification of added benefit is used to inform pricing negotiations between the umbrella organization of statutory health insurance and the pharmaceutical companies.Keywords
This publication has 11 references indexed in Scilit:
- Studying noncollapsibility of the odds ratio with marginal structural and logistic regression modelsStatistical Methods in Medical Research, 2016
- Meta‐analysis of clinical trials with early stopping: an investigation of potential biasStatistics in Medicine, 2013
- Methods to convert continuous outcomes into odds ratios of treatment response and numbers needed to treat: meta-epidemiological studyInternational Journal of Epidemiology, 2012
- Reflections on meta-analyses involving trials stopped early for benefit: Is there a problem and if so, what is it?Statistical Methods in Medical Research, 2011
- Assessing Cancer Drugs for Reimbursement: Methodology, Relationship between Effect Size and Medical NeedTherapies, 2010
- The Relative Merits of Risk Ratios and Odds RatiosArchives of Pediatrics & Adolescent Medicine, 2009
- Treatment Success in CancerNew Cancer Treatment Successes Identified in Phase 3 Randomized Controlled Trials Conducted by the National Cancer Institute–Sponsored Cooperative Oncology Groups, 1955 to 2006Archives of internal medicine (1960), 2008
- Issues in the selection of a summary statistic for meta‐analysis of clinical trials with binary outcomesStatistics in Medicine, 2002
- Numbers needed to treat derived from meta-analyses---sometimes informative, usually misleadingBMJ, 1999
- Test statistics and sample size formulae for comparative binomial trials with null hypothesis of non‐zero risk difference or non‐unity relative riskStatistics in Medicine, 1990